Europe PMC

Background The impact of traditional systemic drugs to treat psoriasis (ciclosporin, methotrexate, and acitretin) in a subsequent response to biologics, has not been adequately addressed in the literature. In clinical practice it is increasingly necessary to initiate, due to concomitant comorbidities, biologics in patients with psoriasis or psoriatic arthritis (PsA) who have not undergone prior treatment with systemics, i.e. full-naive.Objectives and methods This study analyzed the possible impa

Background The impact of traditional systemic drugs to treat psoriasis (ciclosporin, methotrexate, and acitretin) in a subsequent response to biologics has not been adequately addressed in the literature. In clinical practice, it is increasingly necessary to initiate, due to concomitant comorbidities, biologics in patients with psoriasis or psoriatic arthritis (PsA) who have not undergone prior treatment with systemics, i.e. full-naive.Objectives and methods This study analyzed the possible impa

No abstract supplied.Weiterlesen

We developed and validated a novel analytical methodology for the precise quantification of deucravacitinib, an oral TYK2 inhibitor for treating moderate-to-severe plaque psoriasis in adults. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed in this method for sensitive detection of the compound in rat plasma. Analytical separation was performed utilizing an ACE C18 column (4.6 × 100 mm, 5-μm particle size) with a carefully optimized mobile phase composition of methanol and

Purpose Psoriasis is a common chronic inflammatory skin disease. Acupoint injection is reported to be used for the treatment of psoriasis, however its mechanism is not yet clear. The study aimed to investigate the efficiency of combined treatment including acupoint injection in the treatment of psoriasis.Patients and methods Here, we compared the efficacy of multiple immune intervention therapy (MII, acupoint injection with BCG-PSN combined with thymosin enteric-coated tablets, levamisole, intra

No abstract supplied.Weiterlesen

Psoriasis is an immune-mediated skin disease manifested in more than 3% of Americans and over 125 million people worldwide. The inflammatory skin condition with an increased rate of keratinocyte turnover involves every level of the skin and exhibits various forms of the disease, including plaque, guttate, inverse, pustular, and erythrodermic psoriasis, as well as disease-associated conditions, such as psoriatic arthritis and nail psoriasis. Innovative treatment has highlighted the importance of

Psoriasis has been linked to various diet-related comorbidities such as metabolic syndrome, type 2 diabetes, and cardiovascular disease. Evidence is lacking on the role of diet in the management of psoriasis and its comorbidities. We aimed to characterise the dietary patterns and quality of diet in individuals living with psoriasis and to assess whether psoriasis severity and comorbidities are associated with diet quality. Using the UK Biobank cohort, individuals identified with psoriasis via se

No abstract supplied.Weiterlesen

Background Polycyclic aromatic hydrocarbons (PAHs) are environmental pollutants with widespread human exposure and have been associated with adverse health outcomes. However, their potential relationship with psoriasis remains insufficiently explored.Objective The aim of this study is to investigate the association between PAH exposure and psoriasis.Methods Data were obtained from the National Health and Nutrition Examination Survey (NHANES) for the periods 2005-2006, 2009-2010, and 2011-2012. W

The correlation between psoriasis with individual cardiometabolic diseases (CMDs), including coronary heart disease (CHD), stroke, hypertension, heart failure (HF), and type 2 diabetes mellitus (T2DM), have yielded conflicting results, and genetic susceptibility's role in modifying these relationships remains unexplored. To investigate the association of psoriasis with the risk of CMDs, and to assess the modified effect of genetic susceptibility on these associations. A total of 390,165 particip

Background The correlation between psoriasis with individual cardiometabolic diseases (CMDs), including coronary heart disease (CHD), stroke, hypertension, heart failure (HF), and type 2 diabetes mellitus (T2DM), have yielded conflicting results, and genetic susceptibility's role in modifying these relationships remains unexplored.Objective To investigate the association of psoriasis with the risk of CMDs, and to assess the modified effect of genetic susceptibility on these associations.Methods

Background In recent years, the prevalence of uveitis among patients with psoriasis has shown a noticeable upward trend. Previous studies have investigated the immunological mechanisms underlying the potential connection between psoriasis and uveitis, but systematic studies exploring their bidirectional relationship is absent. This study aims to systematically evaluate the bidirectional association between psoriasis and uveitis to provide evidence.Methods We thoroughly searched PubMed, Embase, a

Down syndrome (DS), also known as trisomy 21, is a genetic condition linked to a higher prevalence of skin disorders, including psoriasis, which affects up to 8% of individuals. DS patients with psoriasis present unique management considerations, including a theoretical increased risk of infectious complications with immunosuppressive therapies. This report includes two cases and a systematic review summarizing available evidence on psoriasis characteristics and treatment outcomes in individuals

Introduction Psoriasis is a chronic, systemic inflammatory disease with significant physical and psychosocial burden. Advances in understanding the pathogenesis of psoriasis, particularly the role of interleukin (IL)23/Th17 axis, have led to the development of selective drugs targeting these cytokines. Among these, IL23 inhibitors (guselkumab, risankizumab, and tildrakizumab), represent the most recent class of biologic drugs approved for the management of moderate-to-severe plaque psoriasis. Si

The aim of this research was to explore the potential causal links between various immune cell profiles and the risk of psoriasis, employing a systematic two-sample Mendelian randomization (MR) analysis. The inverse variance weighted (IVW) model is the most commonly used two-sample MR analysis method for estimating the causal effect of exposure on outcomes. In addition to the IVW, we also used the weighted median method, the MR Egger method, and Steiger test as sensitivity analyses. Sensitivity

Background Psoriasis skin lesions are generally thought to occur before psoriatic arthritis (PsA) develops. However, PsA may be challenging to diagnose in the absence of psoriasis and might be underdiagnosed when occurring before psoriasis. We tested the hypothesis that PsA may commonly occur before psoriasis, but without psoriasis skin lesions, is diagnosed as another form of arthritis.Methods A single-center retrospective chart review was performed to identify patients with qualifying diagnose

Few studies have examined the features of patients with IgA nephropathy secondary to psoriasis (IgAN-Pso); leaving the long-term renal outcomes and risk factors for this group unclear. A total of ninety patients with IgAN without evidence of a secondary cause other than psoriasis were enrolled in this retrospective study. The participants were categorized into two groups: the mild-to-moderate psoriasis group (n = 74) and the severe psoriasis group (n = 16). A comparative analysis was conducted o

Background Psoriatic Arthritis (PsA), an immune mediated inflammatory arthritis, affects a quarter of patients with cutaneous psoriasis, usually after psoriasis onset. Early diagnosis of PsA is challenging. A biomarker-based diagnostic test may facilitate early diagnosis.Objectives We aimed to determine whether specific clinical features or genetic and protein markers, alone or in combination, can distinguish patients with PsA from those with psoriasis without PsA (PsC).Methods Patients with PsA

Objectives To investigate the prevalence of psoriasis in SLE using a Swedish regional cohort and a nationwide cohort from the National Patient Register (NPR). Furthermore, we compared clinical features between patients with and without comorbid psoriasis.Methods In total, 351 patients diagnosed with SLE based on the 1982 American College of Rheumatology and/or the 2012 Systemic Lupus International Collaborating Clinics criteria from Linköping University Hospital were evaluated. We obtained patie

Background Biologics effectively improve psoriatic skin lesions, but their impact on itch relief remains unclear.Objective To evaluate itch improvement in severe psoriasis patients treated with ustekinumab or guselkumab.Methods This retrospective study analyzed patients with severe psoriasis who completed initial efficacy evaluations after treatment with either biologic. Itch severity was assessed using numerical rating scale (NRS), visual analog scale, and verbal rating scale. NRS improvement w

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) psoriatic arthritis (PsA) working group provided updates at the GRAPPA 2024 annual meeting on their assessment of composite outcome measures for PsA. The group presented the progress of a systematic literature review on the psychometric properties of the following candidate composite outcome measures using the OMERACT filter 2.2: (1) minimal disease activity (MDA), (2) D

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen